S-8877 Sunitinib, Free Base, >99%

Synonyms : [PHA-290940AD] [PNU-290940AD] [SU-11248]

Related Terms : [Sutent]

  • Size
  • US $
  • £
  • ¥
  • 300 mg
  • 44
  • 41
  • 35
  • 6,800
  • Add to Cart
  • Out of stock
  • 500 mg
  • 57
  • 53
  • 45
  • 8,800
  • Add to Cart
  • Out of stock
  • 1 g
  • 72
  • 67
  • 57
  • 11,100
  • Add to Cart
  • Out of stock
  • 2 g
  • 118
  • 111
  • 94
  • 18,200
  • Add to Cart
  • Out of stock
  • 5 g
  • 238
  • 224
  • 191
  • 36,700
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 398.47
  • C22H27FN4O2
  • [557795-19-4]
  • M.I. 14: 9000

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 40 mg/mL; soluble in ethanol at 1.4 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubilit. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • July 27, 2023:  we expect our next  lot of  S-8877 Sunitinib, Free Base to be ready to ship during the week of August 14, 2023 or sooner.
  • More than 820 labs worldwide have purchased Sunitinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • This is the free base form of sunitinib; please see our product Sunitinib, Malate Salt, Cat. No. S-8803, for further technical information. The malate salt form of sunitinib, not the free base, is used in the sunitinib formulation for use in humans.
  • Sunitinib (as the malate) is the active ingredient in the drug sold under the trade name Sutent®. This drug has been approved in at least one country for the treatment of patients having gastrointestinal stromal tumors or renal cell carcinoma.  Progressive, well-defferentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. NOTE: THE SUNITINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT SUTENT®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.